Lineage Cell Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2016-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2015-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2015-06-30 was 66.45K shares, a 5.06% decline year-over-year.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2015-03-31 was 89.08K shares, a 97.95% increase year-over-year.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2012 was 98.54K shares.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2010 was 125.00K shares, a 0.00% change from fiscal 2009.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2009 was 125.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-05-10 | |
| 2015-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | |
| 2015-06-30 | 66.45K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | |
| 2015-03-31 | 89.08K shares 10-Q · filed 2015-05-08 | |
| 2014-09-30 | 1.95M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | |
| 2014-06-30 | 70.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | |
| 2014-03-31 | 45.00K shares 10-Q · filed 2014-05-12 | |
| 2013-09-30 | 0.00 shares 10-Q · filed 2013-11-12 | 0.00 shares derived: sum of 4 quarters · filed 2014-03-17 |
| 2013-06-30 | 0.00 shares 10-Q · filed 2013-08-09 | 78.54K shares derived: sum of 4 quarters · filed 2014-03-17 |
| 2013-03-31 | 0.00 shares 10-Q · filed 2013-05-10 | 78.54K shares derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | 98.54K shares 10-K · filed 2014-03-17 |
| 2012-09-30 | 78.54K shares 10-Q · filed 2012-11-09 | |
| 2012-06-30 | 0.00 shares 10-Q · filed 2012-08-09 | |
| 2010-12-31 | 125.00K shares 10-K · filed 2013-03-18 | |
| 2009-12-31 | 125.00K shares 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |